In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, be­ta-tha­lassemia

Ver­tex and CRISPR Ther­a­peu­tics have won the first-ever ap­proval for a ther­a­py cre­at­ed with CRISPR gene edit­ing, as the UK drug reg­u­la­tor MHRA green­lights their treat­ment for two blood dis­or­ders.

The ther­a­py pre­vi­ous­ly known as exa-cel will now be brand­ed Cas­gevy. It is au­tho­rized to treat sick­le cell dis­ease and trans­fu­sion-de­pen­dent be­ta-tha­lassemia.

“To­day is a his­toric day in sci­ence and med­i­cine: this au­tho­riza­tion of Cas­gevy in Great Britain is the first reg­u­la­to­ry au­tho­riza­tion of a CRISPR-based ther­a­py in the world,” said Ver­tex CEO Resh­ma Ke­wal­ra­mani in a Tues­day state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER